Covid19
Conditions
Keywords
Saliva Antigen, Rapid Saliva Test
Brief summary
The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19. The Therma COVID-19 Rapid Antigen Test will be compared to a Health Canada approved RT-PCR COVID-19 test. Nasopharyngeal (for RT-PCR) samples will be collected at a COVID-19 Testing centre and saliva (for the rapid antigen test) samples will be collected and compared. The prospective, observational, feasibility study will test 300 participants to establish the performance characteristics of the test on saliva specimens.
Interventions
DEVICETheram COVID-19 Rapid Antigen Test
The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
Sponsors
Cannabis Research Associates
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participant is willing to sign verbal informed consent form 2. Age 12 or older and parents or legal guardians must consent for children as required by law. 3. Participant is attending COVID-19 testing centre for a nasopharyngeal swab sample 4. Participant is willing to provide a self-collected saliva sample
Exclusion criteria
1\. Participant has previously tested positive for COVID-19 within the past 90 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Establish Performance of Therma COVID-19 Rapid Antigen Test | 1 day | To establish the performance characteristics of the Therma COVID-19 Rapid Antigen Test in a near-patient, point-of-care (POC) setting with lay users (no laboratory experience) testing a participant that has self-collected the saliva specimen. Clinical accuracy of the rapid antigen test compared to RT-PCR test results. Accuracy refers to the (PPA, positive percent agreement (sensitivity) and (NPA, negative percent agreement (specificity) between the results of the tests. The expected performance of the test for symptomatic participants shall be \>90% PPA and \>98% NPA. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participant Feedback | 1 day | Evaluate participant feedback on the usability of the Therma COVID-19 Rapid Antigen Test and saliva collection device using the Participant Study Questionnaire Form (Ease of use 5-point scale from 5=Easy to 1=Hard) |
| User Feedback | 1 day | Evaluate user feedback on the usability of the Therma COVID-19 Rapid Antigen Test and saliva collection device using the Therma Feasibility Study User Feedback Questionnaire (ease of use 5-point scale from Not at all to Very easy) |
Contacts
Primary ContactLisa Patterson, BA
Backup ContactIra Price, MD
Outcome results
None listed